A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

608

Participants

Timeline

Start Date

June 27, 2018

Primary Completion Date

July 15, 2020

Study Completion Date

November 30, 2025

Conditions
Ureteral CancerUrothelial CancerBladder Cancer
Interventions
DRUG

Enfortumab Vedotin

Intravenous infusion

DRUG

Docetaxel

Intravenous infusion

DRUG

Vinflunine

Intravenous infusion

DRUG

Paclitaxel

Intravenous infusion

Trial Locations (158)

10065

Sidney Kimmel Center for Prostate and Urologic Cancers, New York

10467

Montefiore Medical Center, The Bronx

10601

White Plains Hospital Center for Cancer Care - Oncology Site, White Plains

11042

Long Island Jewish Medical Center, Lake Success

14263

Roswell Park Cancer Institute, Buffalo

19104

University of Pennsylvania, Philadelphia

19111

Fox Chase Cancer Center, Philadelphia

29607

Saint Francis Hospital, Greenville

32804

Florida Hospital, Orlando

33136

Sylvester Comprehensive Cancer Center, Miami

40207

Norton Cancer Institute, Louisville

43623

Toledo Clinic Cancer Center, Toledo

53226

Medical College of Wisconsin, Milwaukee

60612

Rush University Medical Center, Chicago

68130

Nebraska Cancer Specialists, Omaha

75701

HOPE Cancer Center of East Texas, Tyler

80045

University of Colorado, Denver

90606

Innovative Clinical Research, Whittier

92868

UCI Chao Family Comprehensive Cancer Center, Orange

95817

University of California, Sacramento

97213

Providence Portland Med Center, Portland

98101

Benaroya Research Institute at Virginia Mason, Seattle

06510

Smilow Cancer Hospital at Yale-New Haven, New Haven

02215

Dana-Farber Cancer Institute, Boston

02903

Lifespan Rhode Island Hospital, Providence

Unknown

Site AR54001, Buenos Aires

Site AU61006, Adelaide

Site AU61001, Miranda

Site AU61004, St Leonards

Site AU61002, Sydney

Site AT43005, Linz

Site AT43001, Salzburg

Site AT43004, Vienna

Site BE32011, Aalst

Site BE32007, Brussels

Site BE32013, Brussels

Site BE32010, Charleroi

Site BE32001, Ghent

Site BE32008, Ghent

Site BE32005, Hasselt

Site BE32003, Leuven

Site BE32009, Liège

Site CA15015, Calgary

Site CA15012, Edmonton

Site CA15014, London

Site CA15002, Montreal

Site CA15007, Montreal

Site CA15011, Oshawa

Site CA15004, Québec

Site CA15008, Saskatoon

Site CA15001, Sherbrooke

Site CA15005, Toronto

Site CA15013, Vancouver

Site DK45003, Aalborg

Site DK45004, Copenhagen

Site DK45001, Herlev

Site FR33021, Besançon

Site FR33009, Bordeaux

Site FR33018, Bordeaux

Site FR33001, Brest

Site FR33016, Caen

Site FR33015, Lyon

Site FR33014, Marseille

Site FR33003, Nice

Site FR33022, Paris

Site FR33005, Pierre-Bénite

Site FR33004, Saint-Mandé

Site FR33002, Strasbourg

Site FR33019, Toulouse

Site FR33006, Villejuif

Site DE49011, Essen

Site DE49008, Heidelberg

Site DE49010, Münster

Site DE49003, Tübingen

Site DE49009, Würzburg

Site IT39008, Arezzo

Site IT39019, Cremona

Site IT39010, Milan

Site IT39025, Modena

Site IT39013, Pisa

Site IT39014, Reggio Emilia

Site IT39004, Terni

Site JP81010, Hirosaki

Site JP81014, Kashiwa

Site JP81007, Sapporo

Site JP81026, Sapporo

Site JP81020, Tsukuba

Site JP81018, Morioka

Site JP81009, Kita-gun

Site JP81002, Yokohama

Site JP81005, Sendai

Site JP81016, Sayama

Site JP81024, Takatsuki

Site JP81008, Bunkyo-ku

Site JP81012, Koto-ku

Site JP81013, Shinjuku-ku

Site JP81011, Ube

Site JP81015, Chiba

Site JP81019, Fukuoka

Site JP81023, Fukuoka

Site JP81004, Hiroshima

Site JP81001, Kyoto

Site JP81017, Niigata

Site JP81003, Okayama

Site JP81022, Osaka

Site JP81021, Tokushima

Site JP81006, Toyama

Site NL31002, Amsterdam

Site NL31003, Amsterdam

Site NL31009, Nijmegen

Site NL31001, Tilburg

Site PT35102, Lisbon

Site PT35105, Lisbon

Site PT35106, Porto

Site RU70002, Ivanovo

Site RU70009, Obninsk

Site RU70005, Omsk

Site RU70015, Vologda

Site KR82006, Daejeon

Site KR82007, Goyang-si

Site KR82012, Hwasun-gun

Site KR82002, Incheon

Site KR82001, Seongnam-si

Site KR82003, Seoul

Site KR82004, Seoul

Site KR82008, Seoul

Site KR82009, Seoul

Site KR82010, Seoul

Site KR82005, Shin

Site ES34010, Badajoz

Site ES34002, Badalona

Site ES34001, Barcelona

Site ES34012, Barcelona

Site ES34023, Barcelona

Site ES34014, Córdoba

Site ES34003, Madrid

Site ES34013, Madrid

Site ES34015, Madrid

Site ES34017, Madrid

Site ES34011, Manresa

Site ES34019, Pamplona

Site ES34005, Seville

Site ES34007, Valencia

Site ES34008, Valencia

Site CH41002, Bern

Site CH41001, Chur

Site TW88602, Kaohsiung City

Site TW88605, Kaohsiung City

Site TW88606, Taichung

Site TW88601, Tainan City

Site TW88604, Taipei

Site TW88607, Taoyuan District

Site GB44005, London

Site GB44006, London

Site GB44004, Metropolitan Borough of Wirral

Site GB44002, Sheffield

Site GB44011, Southampton

Site GB44013, Sutton

All Listed Sponsors
collaborator

Seagen Inc.

INDUSTRY

lead

Astellas Pharma Global Development, Inc.

INDUSTRY